Single-Isomer Science: the Phenomenon and Its Te Rm I N O L O G Y by Joseph Gal, Phd

Total Page:16

File Type:pdf, Size:1020Kb

Single-Isomer Science: the Phenomenon and Its Te Rm I N O L O G Y by Joseph Gal, Phd Academic Supplement Single-Isomer Science: The Phenomenon and Its Te rm i n o l o g y By Joseph Gal, PhD ABSTRACT For more detailed information, the reader is re f e rred to text- Single-isomer drugs are of great importance in modern books of basic organic chemistry; advanced treatments of therapeutics. In this article, the basics of the underlying the subject are also available, including an excellent mono- phenomenon are explained. Some molecules are chiral, ie, g r a p h 3 and a highly informative and entertaining volume on their mirror image is not superposable on the original. The a broad variety of aspects of the phenomenon.4 most common element producing molecular chirality is a chiral center, typically a carbon atom carrying four diff e r- MIRROR, MIRROR ON THE WALL... ent groups. The mirro r-image molecules are termed e n a n- C e rtain objects have the pro p e rty that their mirror image t i o m e r s , but the less specific terms s t e r e o i s o m e r s a n d is not entirely identical with the original. The most familiar isomers are also used. A substance consisting of only one of tools for the illustration of this phenomenon are the two the two enantiomers is a single enantiomer or single iso- human hands. If one holds, say, the left hand in front of a m e r, and the 1:1 mixture of the enantiomers is the racemic m i rro r, one finds that the image in the mirror is that of the m i x t u re or racemate. A graphical convention that conveys right hand. Clearly, the right hand is the mirror image of the the three-dimensional aspects of chiral molecules drawn in left hand, and vice versa. Furt h e rm o re, while the two hands two dimensions, as well as two nongraphical conventions, of an individual are identical in appearance, one cannot based on optical rotation and configuration, are used to “ m e r ge” perfectly the left hand into the right one (or the identify enantiomers. Optical rotation is a physical pro p- right hand into the left). This is in contrast to the mirro r e r ty of single enantiomers and involves rotation of the image of another kind of object, eg, the cue ball used in bil- plane of plane-polarized light, each pure enantiomer rotat- l i a r ds. The mirro r-image of the ball is identical in all ing with equal magnitude but in the opposite dire c t i o n respects to the original and is indistinguishable from it. (dextro and levo). Configuration is the actual arrangement F u rt h e rm o re, the mirror image of the ball can be fully and in space of the atoms of chiral molecules. Two systems of p e rfectly “merged” into the original. Thus, the mirror image indicating configuration are in use. One employs D and L of the ball is superposable on the original, while the mirro r to denote the respective enantiomers, and is applicable only image of a hand is not superposable on its original. to α-amino acids and carbohydrates. The other is a univer- An object whose mirror image is not superposable on the sal system using R and S as descriptors for the two possible original is termed c h i r a l (ch p ronounced as k and the word a r rangements, re s p e c t i v e l y, of the atoms around the chiral rhymes with viral), and the phenomenon is called c h i r a l i t y, c e n t e r. Interest in chiral drugs stems from the fre q u e n t l y f rom χειρ (cheir), the Greek word for the hand. H a n d e d n e s s o b s e r ved biological diff e r ences between enantiomers. Such is also a useful term to refer to the phenomenon of chirality. enantioselectivity is the result of diff e rent interactions of Chiral objects abound in nature—indeed, the presence of the drug enantiomers with target receptors that are them- chirality ranges from the subatomic to the macro s c o p i c selves chiral and single-enantiomeric. w o r l d . 4 , 5 M a c r oscopic chiral objects include, for example, C N S S p e c t ru m s . 2002;7(suppl 1):8-13 anatomical parts—eg, the hands, feet, and ears—and some c o rresponding clothing items—eg, gloves and shoes— are INTRODUCTION also chiral. Helical or spiral stru c t u res also have handed- Single-isomer drugs have assumed a great deal of impor- ness, eg, screws are chiral, one form having a left-handed tance in recent years, and are poised to become even more t h read and its mirror image a right-handed thread. Helical significant in the future . 1 , 2 The foundation of single-isomer sea shells, similarly, have right-handed or left-handed helic- d rugs is a chemical phenomenon involving the thre e - d i m e n- ity and are chiral; in arc h i t e c t u r e, columns with a spiral sional aspects of molecules (stere o c h e m i s t ry), and a thor- design have handedness (Figure 1).6 The umbilical cord is ough appreciation of the basic and clinical sciences of chiral by virtue of its helical vasculature, and it has been single-isomer drugs is not possible without an understand- shown that left-handed helices predominate in at least one ing of the pertinent fundamentals and terminology of the n e w b o rn population.7 phenomenon. The purpose of this article, there f o re, is to H o w e v e r, our concern here is with molecules and dru g s , p rovide a description of the basic relevant concepts and lan- and we must there f o re turn our attention from the world of guage. Naturally, the discussion will be limited in scope and m a c r oscopic chiral objects to the world of molecules and will be aimed at the non-expert in organic stere o c h e m i s t ry. chemical compounds. Interest in chiral drugs stems fro m D r. Gal is professor of medicine, pharm a c o l o g y, and pathology in the Division of Clinical Pharmacology at the University of Colorado School of Medicine in Denver. M e d Works Media 8 April 2002 Academic Supplement the fact that the two mirro r-image forms of such substances merism exist, with chirality being the basis of one type. often differ significantly, even drastically, in their biological Thus, the two mirro r-image chiral molecules can be e ffects (see below). termed stereoisomers, but this term is general and not spe- cific to chirality. The precise term for the two mirro r- MOLECULAR HANDEDNESS image stereoisomers is e n a n t i o m e r ( f r om the Gre e k Some molecules are chiral by virtue of the presence of a enantios, opposite), and should be used for rigorous accu- c h e m i c a l - s t ructural element that produces chirality. The most r a c y. However, stereoisomer is often used in the chirality common structural chiral element producing chirality is a context to refer to enantiomers. Furt h e rm o re, in the phar- carbon atom with a specific pattern of groups connected to it maceutical and pharmacological context, enantiomer is (substitution pattern). When a carbon atom has four diff e re n t often replaced with isomer, an even less specific term chemical groups (substituents) bonded to it, the geometric than stereoisomer but one which has nevertheless come shape of the bonding arrangement is in the form of a tetrahe- into use in re f e rence to the enantiomers of chiral dru g s d ron. For example, in the molecule shown in Figure 2, the because of its more familiar nature and short form. carbon atom carries four substituents––hydrogen (H), fluorine Overall, then, a compound that is made up of only one of (F), chlorine (Cl), and bromine (Br)––and the four bonds point the two possible mirro r-image molecules is often re f e rred to t o w a rd the four corners of a tetrahedron. Such a carbon atom as a single enantiomer, single stere o i s o m e r, or, again, some- in a molecule is called a chiral center, and the molecule in what loosely, as a single isomer. When the chemist synthe- F i g u re 2 is chiral, ie, it can exist in two forms that are non- sizes compounds made up of chiral molecules using superposable on each other and are related as an object and o rd i n a ry chemical reactions, the product obtained is usually its mirror image. An overwhelming majority of chiral mole- the 1:1 mixture of the two enantiomers, called the r a c e m i c cules owe their chirality to the presence of a carbon chiral m i x t u re o r, simply, the r a c e m a t e.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Schistosoma Mansoni
    Pharmacological and pharmacokinetic studies on trematocidal drugs : praziquantel and two synthetic peroxide lead candidates INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Isabel Meister aus Neuchâtel (NE) Basel, 2017 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch This work is licensed under a Creative Commons Attribution 4.0 International License. Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Jennifer Keiser Prof. Dr. Piero Olliaro Basel, den 23. Juni 2015 Prof. Dr. Jörg Schibler Dekan Table of Contents Acknowledgements ................................................................................................................................ III Summary ................................................................................................................................................. V List of abbreviations ............................................................................................................................ VII Chapter 1. General introduction ..............................................................................................1 1.1 Trematode biology and life cycle ...............................................................................................2 1.2 Epidemiology and clinical aspects .............................................................................................5
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Seminar on Drug Chirality
    Drug chirality: Stereoselectivity in the action and disposition of anaesthetic agents Isomerism Isomers: Drugs with the same chemical composition and molecular formula. Isomers Structural Stereoisomers isomers •Constitutional / Structural isomerism: Same molecular formula but different chemical structure as the arrangement of atoms is different. Stereoisomerism: Same molecular formula and chemical structure but a different configuration (i.e. different three dimensional spatial arrangement of their atoms) Two types: 1. Optical isomers 2. Geometrical isomers Optical isomerism Enantiomers: A pair of stereoisomers that are non-superimposable mirror images of each other. Cause of enantiomerism: presence of a chiral centre. Physiochemical properties ( solubility, melting and boiling points, ionization constant) are identical. Separation is difficult. Diastereomers: Stereoisomers that are not mirror images of each other and are not enantiomeric. Physiochemical properties are different. Separation is easy. What is chirality? Chiral - derived from a Greek word chiros, meaning handedness. A molecule or object that is not superimposable on its mirror image is said to be chiral. Chiral centre / asymmetric carbon / stereogenic centre – A carbon atom attached to four different substituents. • Achiral molecules usually contain a plane of symmetry but chiral molecules do not. • A plane of symmetry is a mirror plane that cuts the molecule in half, so that one half of the molecule is a reflection of the other half. • With chiral compounds, the plane of the polarized light is rotated through an angle . A compound that rotates polarized light is said to be optically active. •With achiral compounds, the light that passes through the compound remains unchanged. A compound that does not change the plane of polarized light is said to be optically inactive.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Chiral Drugs for You and Me
    Teaching Chemistry Through The Jigsaw Strategy Example 1 Topic Thalidomide: A Controversial Chiral Drug Subtopics 1. Why is drug chirality important? 2. What caused the thalidomide tragedy? 3. Why has thalidomide been approved for sale again? Level Secondary 6-7 Curriculum Links Stereoisomerism Enantiomerism Chiral carbon compounds Medium of instruction English Copyright © 2007 by Quality Education Fund, Hong Kong All rights reserved. Prepared by Professor Derek Cheung, The Department of Curriculum and Instruction, The Chinese University of Hong Kong. No part of this document may be reproduced in any manner whatsoever without written permission, except in the case of use as instructional material in a school by a teacher. 1 1. Why is drug chirality important? Enantiomers are optical isomers which are nonsuperimposable mirror-image structures. The property of nonsuperimposability is called chirality. A molecule is chiral if and only if it is not superimposable on its mirror image. The most common chiral centre is carbon. When four nonidentical atoms or groups are attached to a tetravalent carbon, the tetrahedral arrangement of the bonds in space results in two enantiomers. Enantiomers can be distinguished by experiments because they have different ability to rotate a beam of plane-polarized light: to the clockwise direction as a dextrorotatory (+)-enantiomer and to the counterclockwise direction as a levorotatory (-)-enantiomer. A mixture of equal portions (50/50) of the (+) and (-) enantiomers is called a racemic mixture. In 1957, a pharmaceutical company in West Germany introduced a new drug to the market. It was called thalidomide with molecular formula C13H10N2O4. The drug was sold in 46 countries under at least 37 brand names.
    [Show full text]
  • Abstract CHIRALITY and ENANTIOMERS CHIRAL DRUGS in BIOLOGICAL SYSTEMS
    Abstract CHIRALITY AND ENANTIOMERS This section contains the basics needed to understand chiral drugs. Undergraduate textbooks in chemistry are good resources for a more thorough discussion of chirality and enantiomers. The most important point is that chiral drugs have 2 structurally similar forms that can behave very differently in biological systems due to their different shapes in 3-dimensional space. These 2 possible forms are termed enantiomers, and the 2 enantiomers of a given chiral drug should be considered 2 different drugs. This topic is discussed further in the next section. Chirality is formally defined as the geometric property of a rigid object (like a molecule or drug) of not being superimposable with its mirror image. Molecules that can be superimposed on their mirror images are achiral (not chiral). Chirality is a property of matter found throughout biological systems, from the basic building blocks of life such as amino acids, carbohydrates, and lipids to the layout of the human body. Chirality is often illustrated with the idea of left- and right-handedness: a left hand and right hand are mirror images of each other but are not superimposable. The 2 mirror images of a chiral molecule are termed enantiomers. Like hands, enantiomers come in pairs. Both molecules of an enantiomer pair have the same chemical composition and can be drawn the same way in 2 dimensions (e.g., a drug structure on a package insert), but in chiral environments such as the receptors and enzymes in the body, they can behave differently. A racemate (often called a racemic mixture) is a mixture of equal amounts of both enantiomers of a chiral drug.
    [Show full text]
  • Enantiomeric Quantification of Psychoactive Substances and Beta Blockers by Gas Chromatography-Mass Spectrometry in Influents of Wastewater Treatment Plants
    Enantiomeric quantification of psychoactive substances and beta blockers by gas chromatography-mass spectrometry in influents of wastewater treatment plants Ricardo Daniel Teixeira Gonçalves Dissertation of the 2nd Cycle of Studies Conducive to the Master’s Degree in Clinical and Forensic Analytical Toxicology, Faculty of Pharmacy, University of Porto Work performed under the orientation of: Professor Doctor Maria Elizabeth Tiritan Professor Doctor Cláudia Maria Rosa Ribeiro September 2018 IT IS NOT PERMITED TO REPRODUCE ANY PART OF THIS DISSERTATION DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A REPRODUÇÃO DE QUALQUER PARTE DESTA DISSERTAÇÃO Agradecimentos Em primeiro lugar gostaria de agradecer às minhas orientadoras (ou mães da ciência), a Professora Doutora Maria Elizabeth Tiritan e a Professora Doutora Cláudia Ribeiro por me terem aceitado (adotado) para poder continuar este projeto. Obrigado por me ajudarem na iniciação de um projeto de raiz, que depois de quatro anos e muitas frustrações, vejo que não foi em vão. Por toda a ajuda, insistência, paciência, preocupação e compreensão que sempre tiveram, o maior obrigado! À Dra. Sara Cravo do laboratório de química orgânica da FFUP, que me recebeu de braços abertos, batalhou comigo durante meses e me deixou usar e abusar do seu laboratório de cromatografia gasosa. Obrigado por toda a ajuda, paciência, explicações, disponibilidade e acima de tudo, por me compreender nos momentos mais desesperantes. Estou-lhe profundamente grato por me fazer sentir “em casa” e por sempre arranjar soluções! Ao Professor Doutor Carlos Afonso do laboratório de química orgânica da FFUP por me autorizar a invadir o laboratório de química orgânica e pela preocupação constante com o progresso do trabalho.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]